Literature DB >> 6697646

Kinetics of epsilon-aminocaproic acid distribution, elimination, and antifibrinolytic effects in normal subjects.

M C Frederiksen, D J Bowsher, T I Ruo, T K Henthorn, C H Ts'ao, D Green, A J Atkinson.   

Abstract

The kinetics of epsilon-aminocaproic acid (EACA) distribution and elimination were studied in six normal subjects after a single 10-gm iv dose. Steady-state distribution volume averaged 30.01 or 0.39 l/kg. Mean elimination t 1/2 was 294 min and the elimination clearance was 0.19 l/min. Renal excretion of unchanged EACA accounted for 68% of its elimination and renal EACA clearance averaged 115% of creatinine clearance. EACA antifibrinolytic effect kinetics were also characterized in five of the subjects by the monitoring of clot lysis times in whole blood and platelet-rich plasma. Peak antifibrinolytic effects were observed 15 to 60 min after peak EACA plasma concentrations were attained. A model of maximal fibrinolysis inhibition (Emax) was used to estimate a half-maximal inhibition (IC50) of 63 +/- 19.7 microgram/ml. This agrees with the value of 0.55 mM or 72 microgram/ml that has been reported for the dissociation constant of the EACA-plasminogen complex and is consistent with the proposed biochemical mechanism of EACA action.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6697646     DOI: 10.1038/clpt.1984.48

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  4 in total

1.  Population pharmacokinetics of ϵ-aminocaproic acid in adolescents undergoing posterior spinal fusion surgery.

Authors:  P A Stricker; M R Gastonguay; D Singh; J E Fiadjoe; E M Sussman; E Y Pruitt; T K Goebel; A F Zuppa
Journal:  Br J Anaesth       Date:  2015-01-13       Impact factor: 9.166

Review 2.  Antifibrinolytic therapy in cardiac surgery.

Authors:  R H Chen; O H Frazier; D A Cooley
Journal:  Tex Heart Inst J       Date:  1995

3.  Population pharmacokinetics of epsilon-aminocaproic acid in infants undergoing craniofacial reconstruction surgery.

Authors:  P A Stricker; A F Zuppa; J E Fiadjoe; L G Maxwell; E M Sussman; E Y Pruitt; T K Goebel; M R Gastonguay; J A Taylor; S P Bartlett; M S Schreiner
Journal:  Br J Anaesth       Date:  2013-01-25       Impact factor: 9.166

4.  Enhanced Antifibrinolytic Efficacy of a Plasmin-Specific Kunitz-Inhibitor (60-Residue Y11T/L17R with C-Terminal IEK) of Human Tissue Factor Pathway Inhibitor Type-2 Domain1.

Authors:  Kanagasabai Vadivel; Anne K Zaiss; Yogesh Kumar; Frank M Fabian; Ayman E A Ismail; Mark A Arbing; Wallace G Buchholz; William H Velander; S Paul Bajaj
Journal:  J Clin Med       Date:  2020-11-17       Impact factor: 4.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.